|
COMMERCE BUSINESS DAILY ISSUE OF MARCH 19,1998 PSA#2055National Cancer Institute, Research Contracts Branch, PCPSS, 6120
Executive Blvd, Room 635, Bethesda, MD 20892-7226 A -- PHASE II -- CLINICAL TRIALS OF NEW CHEMOPREVENTIVE AGENTS SOL RFP
No. N01-CN-85077-57 POC Desiree E. Sylver-Foust, Contract Specialist,
301-435-3833 WEB: N01-CN-85077-57 -- Phase II Clinical Trials of New
Chemopreventive Agents, http://rcb.nci.nih.gov/RFP.HTM. E-MAIL: Desiree
E. Sylver-Foust, ds154o@nih.gov. ELECTRONIC RFP ANNOUNCEMENT: POTENTIAL
OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE
SOLICITATION AND AMENDMENTS.) The Division of Cancer Prevention (DCP),
National Cancer Institute (NCI), National Institute of Health (NIH),
intends to expand the existing Master Agreement (MA) pool for "Phase II
Clinical Trials of New Chemopreventive Agents". Offerors selected for
award of a MA may be solicited to provide the adequate capabilities and
technical expertise to furnish all necessary services, qualified
personnel, materials and supplies and facilities to carry out the
objective of this MA which is to encourage cancer chemoprevention
clinical trials that use biochemical and biological markers as
intermediate endpoints. The application of biological markers to
clinical prevention trials carries great promise in relation to
ultimate cancer prevention. When cancer incidence reduction itself is
ued as an endpoint in studies of this type, a very large number of
subjects tested for long durations is often required. The design of
phase 2a clinical trials will be small, short-term, efficient studies
that determine the dose-response of a given chemopreventive agent on
pharmacological and intermediate endpoints, the minimum dose at which
this biological effect is observed, and the maximum safe dose. The
second segment phase 2b study will involve a randomized,
placebo-controlled, blinded trial in a small group of subjects in which
the endpoint will be a modulation of a quantifiable biological effect
that is correlated with cancer incidence reduction in the agent versus
the placebo treated groups. Master Agreements will be awarded to all
respondents whose technical proposal is considered acceptable. The
Master Agreement award is a non-monetary and is exclusively for the
purpose of compiling a pool of contractors who are pre-qualified to
perform services to perform specific Phase II studies. Each Master
Agreement holder will be eligible to compete for future contract awards
to carry out specific Phase IIstudies. Master Agreement holders
receiving a contract award will be selected through this pool, based on
technical merit and on budgetary considerations for specific tasks
involved. Any MA awarded as a result of this solicitation will be in
effect from the effective date to October 30, 2002. This solicitation
will be open for the duration of the existing MA Pool with due dates
for receipt of proposals semi-annually, June 1 and December 1 (or the
next business day) of each year. All responsible sources meeting these
criteria are encouraged to submit a proposal and a sample requirement
to be considered by the NCI. ALL MA HOLDERS ALREADY IN THE EXISTING MA
POOL NEED NOT RESPOND TO THIS ANNOUNCEMENT. The RFP may be accessed
through the Research Contracts Branch Home Page by using the following
Internet address: http://rcb.nci.nih.gov/rfp.htm. It is the offeror's
responsibility to monitor the above internet site for the release of
this solicitation and amendments, if any. POTENTIAL OFFERORS WILL BE
RESPONSIBLEFOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND
AMENDMENTS. (Hard copies will be available only upon individual
request). Point of contact: Desiree Sylver-Foust, Contract Specialist,
NCI, RCB, PCPSS; 6120 Executive Boulevard, Executive Plaza South, Room
635, Rockville, MD 20852; Email address:ds1540@nih.gov.; Telephone:
(301) 435-3833; Fax (301) 402-8579. All requests should reference the
RFP No. N01-CN-85077-57. No collect calls will be accepted. Numbered
Note 26 -- Based upon market research, the Government is not using the
policies contained in Part 12, Acquisition of Commercial Items, in its
solicitation for the described supplies or services. However,
interested persons may identify to the contracting officer their
interest and capability to satisfy the Government's requirement with a
commercial item within 15 days of this notice. (0075) Loren Data Corp. http://www.ld.com (SYN# 0001 19980319\A-0001.SOL)
A - Research and Development Index Page
|
|